Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18655582 | 1.00 | TSHR (0.59) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17142884 | 0.92 | TSHR (0.69) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL17143201 | 0.92 | TSHR (0.69) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2151432 | 0.92 | TSHR (0.69) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL25457757 | 0.90 | TSHR (0.67) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22207294 | 0.90 | TSHR (0.67) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22207087 | 0.90 | TSHR (0.67) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22207378 | 0.90 | TSHR (0.67) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22207278 | 0.90 | TSHR (0.67) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL22207311 | 0.90 | TSHR (0.67) | TSHRSMPD1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170084841-A1 | FUSED BIS-ARYL FULLERENE DERIVATIVES | NANO-C, INC. | 2017-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170084841-A1 | FUSED BIS-ARYL FULLERENE DERIVATIVES | OCIAD2, PPOX, OCIAD1 | TSHR 4597/4885SMPD1 4875/4885CYP1A2 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.